Abstract CT056: A multicenter, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of MORAb-202, a folate-receptor-alpha-targeting antibody-drug conjugate in patients with selected tumor types
Year: 2023
Type: conference-abstract
Source: Cancer Research
Institutions: Moffitt Cancer Center, Augusta University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Weill Cornell Medical Center, Columbia University Irving Medical Center, University of Virginia, Winship Cancer Institute, Eisai (United Kingdom), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365512807